Preparation of bismuth sulfide nanoparticles as targeted biocompatible nano‐radiosensitizer and carrier of methotrexate. (8th November 2019)

• Record Type: Journal Article
• Authors: Azizi, Sedigheh; Nosrati, Hamed; Sharafi, Ali; Danafar, Hossein
• Is Part Of: Applied organometallic chemistry. Volume 34:Number 1(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-11-08
• Subjects: biocompatibility -- biotin -- bismuth sulfide -- carbodiimide chemistry -- X‐ray radiation; Organometallic chemistry -- Periodicals; Organometallic compounds -- Periodicals; 547.05
• DOI: 10.1002/aoc.5251
• Languages: English
• ISSNs: 0268-2605

Abstract

Abstract : In this study, Bi2 S3 @BSA–Bio–MTX nanoparticles (NPs) were synthesized for the first time by bovine serum albumin (BSA)‐mediated biomineralization (Bi2 S3 @BSA NPs) followed by covalent bonding of biotin (Bio) and methotrexate (MTX) on the surface of the Bi2 S3 @BSA NPs via carbodiimide chemistry. The synthesized NPs were globular and exhibited uniform morphology with a hydrodynamic diameter of 107.6 ± 6.81 nm (mean ± standard deviation) and zeta potential of −20.9 ± 2.18 mV. Drug release from Bi2 S3 @BSA–Bio–MTX NPs indicated an enzyme‐dependent release pattern. The in vitro biocompatibility of NPs was confirmed by investigating their cytotoxicity against the HEK‐293 cell line and hemolysis assay test, whereas the in vivo biocompatibility of the NPs was evaluated and confirmed by the lethal dose 50 (LD50 ) test. To evaluate the in vitro anticancer activity of the functionalized NPs and MTX, their cytotoxic effects was assessed against 4T1 cancer cells by 5‐dimethylthiazol‐z‐yl)‐2, 5‐diphenyltetrazolium bromide (MTT) assay with and without X‐ray radiation. Results showed that Bi2 S3 @BSA–Bio–MTX NPs have excellent anticancer activity, especially following X‐ray radiation. Abstract : Biocompatible Bi2 S3 @BSA–Bio–MTX nanoparticles (NPs) were synthesized by biomineralization (Bi2 S3 @BSA NPs) followed by covalent bonding of biotin (Bio) and methotrexate (MTX) on the surface of the Bi2 S3 @BSA NPs via carbodiimide chemistry. In vitro antitumor activity of the NPs was assessed on 4T1 cancer cells using 5‐dimethylthiazol‐z‐yl)‐2, 5‐diphenyltetrazolium bromide (MTT) assay with and without X‐ray radiation. Results showed that Bi2 S3 @BSA–Bio–MTX NPs have excellent anticancer activity, especially following X‐ray radiation.